Merck Diversifies Portfolio to Counter Keytruda Patent Cliff

Merck & Co. is implementing a multi-pronged strategy to sustain its market position and dividend growth as the patent for its top-selling oncology drug, Keytruda, faces expiration by 2028. To mitigate the impact of this patent cliff, the company is developing a pill version of Keytruda and has secured approval for a subcutaneous formulation to extend protections and improve patient convenience.

The company is also diversifying its portfolio to reduce reliance on Keytruda. Recent launches include Capvaxive, a pneumonia vaccine, and Winrevair, a treatment for pulmonary arterial hypertension. These efforts come as Merck faces increased competition, specifically from Summit Therapeutics, whose drug ivonescimab outperformed Keytruda in clinical trials for non-small cell lung cancer.

Despite revenue declines in its Gardasil HPV vaccine franchise, Merck remains an attractive option for long-term investors. The company's shares rose 46% over the past year, supported by a forward dividend yield of 2.8%, which exceeds both the S&P 500 and pharmaceutical sector averages. Merck maintains a payout ratio of approximately 45% and a 35-year history of steady dividend increases.